Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Non-steroidal anti-inflammatory drugs |
| Generic Name : | Lornoxicam |
| Drug description : | Film-coated tablets. |
| Presentation : | Tablets, lornoxicam 4mg, 8mg. |
| Indications : | Short-term treatment of moderate postoperative pain, such as pain after dental surgery. Treatment of pain associated wih acute lumbo-sciatia. Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. |
| Adult Dosage : | Postoperative pain/acute lumbo-sciatia, recommended daily dose, 8mg to 16mg taken before meals (daily doses above 8mg should be divided into two or more doses). Maximum single dose, 8mg; maximum daily dose, 16mg. Osteoarthritis/Rheumatoid arthritis, recommended daily dose, 12 mg taken before meals (4mg three times daily or 8mg in the morning and 4mg at night); maximum recommended daily dose for long-term treatment, 12mg. |
| Child Dosage : | Under 18 years, not recommended |
| Elderly Dosage : | Monitoring of renal and heptic function is recommended. |
| Contra Indications : | Allergy to lornoxicam or any of the excipients. Previous hypersensitivity reactions (symptoms like asthma, rhintis, angioedema or urticaria) to other non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin (acetylsalicylic acid). Active peetic ulceration or a history of recurrent peptic ulceration. Severe renal impairment (serum creatinine > 700 micromol/ml). Pregnancy and lactation. Patients under 18 years of age. |
| Special Precautions : | In the following conditions Xefo should be administered only after careful risk-benefit asseseement. Gastrointestinal ulceration and bleeding in medical history; discontinue treatment if peptic ulceration and/or gastrointestinal bleeding occurs. Renal impairment: mild (serum creatinine 150 to 300 micromol/l), monitor at one to two month intervals. Blood coagulation disorders; careful monitoring recommended. Liver disease (eg, cirrhosis); regular monitoring recommended. Long-term treatment (longer than three months), monitor haemoglobin, creatinine and liver enzymes regularly. Elderly; monitor renal and hepatic function in patients over 65 years. Hypertension and/or obesity; monitor blood pressure and renal function. Monitor renal function in patients who are to undergo major surgery, with stressed renal function (eg, as a result of significant blood loss or severe dehydration), with cardiac failure, receiving concomitant treatment with diuretics or with drugs suspected or known to be able to cause kidney damage. |
| Interactions : | Anticoagulants or platelet aggregation inhibitors, sulphonylureas, other NSAIDs, diuretics, beta-blockers, ACE inhibitors, lithium, methotrexate, cimetidine, digoxin. |
| Adverse Reactions : | Most commonly (frqency 1 to 10%): abdominal pain, diarrhoea, dizziness, dyspepsia, headache, nausea, vomiting. Rarely (frequency <1%): constipation, dysphagia, dry mouth, flatulence, gastritis, gastro-oesophageal reflux, peptic ulceration and/or gastrointestinal bleeding, stomatitis, haemorrhoidal bleeding, liver function abnormalities, alopecia, dermatitis, pruritus, increased sweating, micturition disorder, oedema, leg cramps paraesthesia, tremor, conjunctivitis, vision disorder, tinnitus, taste perversion, allergic reactions, anaemia, thrombocytopenia, increased bleeding time, ecchymoses, hypertension, palpitations, tachycardia, agitation, depression, insomnia, solnolence, alteration in appetite, weight changes, mylagia, malaise, weakness. |
| Manufacturer : | CeNeS |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org